Lexington Medical Center

Lexington Medical Center
2720 Sunset Blvd.
West Columbia, SC 29169
803-791-2000

Contacts
Taylor Knight, Research Coordinator: tvknight@lexhealth.org
Selena Lollar, Research Coordinator: swlollar@lexhealth.org
Kate Madden, Research Coordinator: kdmadden@lexhealth.org

As an affiliate of the Medical University of South Carolina, Lexington Medical Center is an active NCORP site. Lexington Medical Center is currently active on the following clinical trials addressing various cancer types. Ask your health care provider for more information.

Breast

• A011801: The CompassHER2 Trials (Comprehensive Use of Pathological Response Assessment to Optimize Therapy in HER2 Positive Breast Cancer): CompassHer2 Residual Disease (RD), A Double Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib.
  This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2-positive breast cancer.
• A012103: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
  To evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab.
• BR008: Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (HERO)
  To compare the recurrence-free interval among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per current standard of care.
• CC011: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors
  To examine the efficacy of computerized cognitive training (BrainHQ) compared to the attention control on perceived cognitive impairment post intervention (12 weeks post-randomization).
• CCTG MA.39: Testing regional radiation therapy in patients with low risk breast cancer.
  This trial studies if not giving regional radiotherapy is just as good as using regional radiotherapy in keeping breast cancer from coming back in patients with estrogen receptor-positive, HER2-negative, node-positive low-risk breast cancer who have undergone breast conserving surgery or mastectomy.
• S2212: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  To assess whether participants with early stage TNBC randomized to receive anthracycline-free, taxane-platinum neoadjuvant chemotherapy with  pembrolizumab have non-inferior breast cancer event-free survival compared to participants randomized to taxane-platinum-anthracycline neoadjuvant chemotherapy with pembrolizumab.
  

Genitourinary — Prostate

• EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers.
  This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.
• S1931: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
  To compare overall survival in participants with newly diagnosed metastatic renal cell carcinoma who are randomized to receive immune checkpoint inhibitor-based combination treatment plus cytoreductive nephrectomy versus immune checkpoint inhibitor-based combination treatment alone.

Thoracic — Lung

• A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo IO.
  This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
• LU008: Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
  To compare overall survival in patients with stage II-IIIC inoperable node-positive non-small cell lung cancer after conventional radiotherapy to the primary tumor and nodal metastases (Arm 1) or after stereotactic body radiation therapy to the primary tumor followed by conventionally fractionated radiotherapy to nodal metastases (Arm 2) both given with concurrent platinum-based chemotherapy.

All Disease Sites

• A212102: Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  To provide a blinded reference set of cancer vs. non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection.